Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.65 |
| ▸ | TTBK1 | Q5TCY1 | 9/20 | 0.59 |
| ▸ | TTBK2 | Q6IQ55 | 8/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787062 | 0.83 | TTBK1 (0.63) | TNNI3KTTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL4787438 | 0.82 | TNNI3K (0.62) | TNNI3KTTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL21620794 | 0.77 | AKT1 (0.49) | TNNI3KTTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL3801686 | 0.76 | KMT2A (0.67) | SRCFGFR1FLT1EPHB2FLT4 | |
| SCHEMBL24881543 | 0.75 | TTBK1 (0.76) | TTBK1TTBK2 | |
| SCHEMBL16961583 | 0.75 | MKNK1 (0.77) | TNNI3KTTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL15618238 | 0.74 | TNNI3K (0.53) | TNNI3KTTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL23565733 | 0.73 | KMT2A (0.61) | — | |
| SCHEMBL4738813 | 0.73 | TTBK1 (1.00) | TNNI3KTTBK1TTBK2BRAF | |
| SCHEMBL1096352 | 0.72 | EGFR (0.51) | SRCFGFR1FLT1EPHB2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | TNNI3K 1832/4885TTBK1 2062/4885TTBK2 1479/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | TNNI3K 2974/4885TTBK1 2093/4885TTBK2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.